SCHEMBL7900928

SCHEMBL7900928

Cc1ccc(NNC(=O)C2(c3ccc(F)cc3)CCN(C(=O)c3ccc(-c4ccc(F)cc4)cc3)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.46
HSD11B1 P28845 2/20 0.46
EPHX2 P34913 2/20 0.43
GABRD O14764 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRB1 P18505 1/20 0.42
GABRA5 P31644 1/20 0.42
GABRA3 P34903 1/20 0.42
GABRA2 P47869 1/20 0.42
GABRB2 P47870 1/20 0.42
GABRA4 P48169 1/20 0.42
HPGD P15428 1/20 0.42
HDAC1 Q13547 1/20 0.41
SLC6A7 Q99884 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TSHR P16473 1/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3107003 0.95 PTPN1 (0.50) PTPN1HSD11B1EPHX2HPGDHDAC1
SCHEMBL3110203 0.90 HSP90AA1 (0.47) PTPN1HSD11B1EPHX2HDAC1
SCHEMBL7907727 0.89 SLC6A7 (0.50) PTPN1HSD11B1HPGDSLC6A7MEN1
SCHEMBL3106971 0.87 PTPN1 (0.45) PTPN1HSD11B1EPHX2HPGDHDAC1
SCHEMBL3227686 0.84 CYP3A4 (0.48) PTPN1HPGDSLC6A7MEN1KMT2A
SCHEMBL13102505 0.82 HDAC1 (0.43) PTPN1HSD11B1HDAC1SLC6A7MEN1
SCHEMBL3092523 0.80 CYP3A4 (0.51) SLC6A7MEN1KMT2ATSHRALDH1A1
SCHEMBL3092692 0.80 FASN (0.48) PTPN1HSD11B1HDAC1SLC6A7MEN1
SCHEMBL13092423 0.79 SLC6A7 (0.50) HSD11B1HPGDSLC6A7MEN1KMT2A
SCHEMBL7900933 0.78 P2RX7 (0.37) PTPN1HSD11B1HPGDHDAC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 PTPN1 1883/4885HSD11B1 3638/4885EPHX2 3464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.